7 High-Tech Winners in Medical Diagnostics and Devices
These names combine healthcare research with state-of-the art technology.
2 Candidates to Consider as Biotech Buyout Activity Picks Up
A handful of deals have been announced this week alone and they give rise to expectations of more acquisitions to come.
Weakening Dollar, Fiscal Relief Gridlock, Walmart+, Trading Albemarle
Also, interpreting Tuesday's market, Covid-19 vaccine update, and manufacturing growth.
Here's a Healthy Investing Opportunity
Centene is a $110 billion in revenue company you've probably never heard of. Here's how to play it.
Vaccine Chills, Divergent Trails, Fed-flation, Walmart and TikTok: Market Recon
Plus, Veeva Systems reports stellar results and ups its guidance.
A Healthy Dose of Vaccine and Pharmaceutical Plays
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
3M Charts Can't Mask a Likely Push Higher Ahead
Shares of the industrial and technology giant have been listless for quite a while but finally appear poised for a rally.
Fluidigm Is Poised Again for Higher Prices as Volume Leads
Do your fundamental homework and consider going long FLDM.
There's a Play to Be Had With Pfizer
Getting dropped from the Dow may give PFE the catalyst it needs to make a big move one way or the other.
Will Mydecine's Move Make the Market for Pharmaceutical Psilocybin Mushroom?
Psychedelic companies hoping to capitalize on a surging interest in psilocybin treatments have been limited to one source for research grade psilocybin. Until now.